Resonance Health (RHT) Stock Overview
A healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RHT Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Resonance Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.048 |
| 52 Week High | AU$0.068 |
| 52 Week Low | AU$0.033 |
| Beta | 1.41 |
| 1 Month Change | -11.11% |
| 3 Month Change | 17.07% |
| 1 Year Change | -15.79% |
| 3 Year Change | -20.00% |
| 5 Year Change | -69.03% |
| Change since IPO | -99.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| RHT | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 4.3% | 1.9% | 0.9% |
| 1Y | -15.8% | -5.6% | 2.1% |
Return vs Industry: RHT underperformed the Australian Medical Equipment industry which returned -5.6% over the past year.
Return vs Market: RHT underperformed the Australian Market which returned 2.1% over the past year.
Price Volatility
| RHT volatility | |
|---|---|
| RHT Average Weekly Movement | 12.0% |
| Medical Equipment Industry Average Movement | 11.3% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 19.2% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: RHT has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: RHT's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Andrew Harrison | www.resonancehealth.com |
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC; HepaFatScan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; HepaFatSmart, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFatSmart into a consolidated report; and CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading.
Resonance Health Limited Fundamentals Summary
| RHT fundamental statistics | |
|---|---|
| Market cap | AU$22.78m |
| Earnings (TTM) | -AU$1.73m |
| Revenue (TTM) | AU$11.07m |
Is RHT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RHT income statement (TTM) | |
|---|---|
| Revenue | AU$11.07m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$11.07m |
| Other Expenses | AU$12.81m |
| Earnings | -AU$1.73m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0037 |
| Gross Margin | 100.00% |
| Net Profit Margin | -15.65% |
| Debt/Equity Ratio | 30.4% |
How did RHT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 17:25 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Resonance Health Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
